Outlook Therapeutics (NASDAQ:OTLK) Announces Earnings Results, Beats Estimates By $0.06 EPS

Outlook Therapeutics (NASDAQ:OTLK) posted its quarterly earnings data on Friday. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.06, Zacks reports.

Outlook Therapeutics Trading Up 17.1 %

NASDAQ OTLK traded up $0.29 during trading hours on Friday, hitting $1.99. The company’s stock had a trading volume of 929,598 shares, compared to its average volume of 696,743. The company’s 50-day simple moving average is $3.88 and its two-hundred day simple moving average is $5.94. The company has a market capitalization of $47.07 million, a PE ratio of -0.19 and a beta of 0.47. Outlook Therapeutics has a 52 week low of $0.87 and a 52 week high of $12.85.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Outlook Therapeutics in a research note on Friday, November 29th. Ascendiant Capital Markets dropped their target price on shares of Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd. Chardan Capital restated a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. Finally, BTIG Research decreased their price target on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 29th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Outlook Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $42.34.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.